Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1066-1079

  Jung, Hyun Joo ^a,b   Chen, Zheng ^a   McCarty, Nami ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Ajou University School of Medicine   (South Korea)

Author keywords

cancer stem cells; cancer initiating cells; chemotherapy resistance; Mantle cell lymphoma; non Hodgkin lymphoma

Indexed keywords

ABC TRANSPORTER; CD19 ANTIGEN; CD45 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CARCINOGENESIS; CELL RENEWAL; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, CD19; ANTIGENS, CD45; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHOMA, MANTLE-CELL; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79957500293     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.562570     Document Type: Article

References (63)

1. Rogers BB. Overview of non-Hodgkins lymphoma. Semin Oncol Nurs 2006;22:67-72.
2. Mounter PJ, Lennard AL. Management of non-Hodgkins lymphomas. Postgrad Med J 1999;75:2-6.
3. Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 2006;91: 11-16. (Pubitemid 43235380)
4. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-127. (Pubitemid 29214065)
5. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009;94:1488-1492.
6. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149-165. (Pubitemid 351994053)
7. Chen Z, Ayala P, Wang M, et al. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 2010;5:212-225.
8. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336. (Pubitemid 38326254)
9. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648. (Pubitemid 24067706)
10. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707. (Pubitemid 36857723)
11. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol 2004;16:708-712. (Pubitemid 39463123)
12. Enguita-German M, Schiapparelli P, Rey JA, Castresana JS. CD133 cells from medulloblastoma and PNET cell lines are more resistant to cyclopamine inhibition of the sonic hedgehog signaling pathway than CD133- cells. Tumour Biol 2010;31:381-390.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
14. OBrien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
15. Cammareri P, Scopelliti A, Todaro M, et al. Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010;70:4655-4665.
16. Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasisanddrug resistance. Cancer Res 2010;70:4602-4612.
17. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
18. Ishii H, Iwatsuki M, Ieta K, et al. Cancer stem cells and chemoradiation resistance. Cancer Sci 2008;99:1871-1877.
19. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006;98:1755-1757. (Pubitemid 46017927)
20. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007;104:618-623. (Pubitemid 46123074)
21. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010;28:4006-4012.
22. Kobune M, Takimoto R, Murase K, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34 leukemic cells. Cancer Sci 2009;100:948-955.
23. Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. Anticancer Drugs 2005;16:277-283. (Pubitemid 40283942)
24. Fruehauf JP, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005;23:3641-3643;author reply 3646-3648.
25. Markasz L, Kis LL, Stuber G, et al. Hodgkin-lymphomaderived cells show high sensitivity to dactinomycin and paclitaxel. Leuk Lymphoma 2007;48:1835-1845. (Pubitemid 47386720)
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
27. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115:207-216.
28. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theoret Biol 1976;59:253-276.
29. Riss TL, Moravec RA. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol 2004;2:51-62. (Pubitemid 38647416)
30. OBrien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000;267:5421-5426.
31. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-966.
32. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-2642. (Pubitemid 39434941)
33. Chaudhary PM, Roninson IB. Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94. (Pubitemid 121001349)
34. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-1166. (Pubitemid 32677289)
35. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-877. (Pubitemid 41060226)
36. Wirths S, Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 2005;35:3433-3441. (Pubitemid 43025524)
37. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010;44:152-167.
38. Martinez-Climent JA, Fontan L, Gascoyne RD, Siebert R, Prosper F. Lymphoma stem cells: enough evidence to support their existence? Haematologica 2010;95:293-302.
39. Romaguera JE. Mantle cell lymphoma: frontline and salvage therapy. Curr Hematol Malign Rep 2008;3:204-209.
40. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469-1476.
41. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma 2009;50:1937-1970.
42. Zhou J, Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 2008;7:1360-1370. (Pubitemid 351872574)
43. Obrador-Hevia A, Fernandez de Mattos S, Villalonga P, Rodriguez J.Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies. Blood Rev 2009;23:205-216.
44. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Educ Program Am Soc Hematol 2009:542-551.
45. Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: current standards and future strategies. Hematol Oncol Clin North Am 2008;22:953-963.
46. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005;23:6409-6414. (Pubitemid 46222241)
47. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223-235.
48. Oh SY, Jang MJ, Chang SK, Oh D, Chong SY. A case of mantle cell lymphoma treated with autologous stem cell transplantation and rituximab. Korean J Hematol 2006;41:215-219.
49. Kaaijk P, Kaspers GJ, Van Wering ER, et al. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 2003;88:775-781. (Pubitemid 36411459)
50. Goto H, Naruto T, Tanoshima R, et al. Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic leukemia cell lines, YCUB series, derived from children. Leuk Res 2009;33:1386-1391.
51. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008;22:179-185.
52. Barzilai A. DNA damage, neuronal and glial cell death and neurodegeneration. Apoptosis 2010;15:1371-1381.
53. Bongaerts GPA. What of apoptosis is important: the decay process or the causative origin. Med Hypoth 2008;70:482-487.
54. Veraitch FS, Al-Rubeai M. Enhanced growth in NS0 cells expressing aminoglycoside phosphotransferase is associated with changes in metabolism, productivity, and apoptosis. Biotechnol Bioeng 2005;92:589-599. (Pubitemid 43014660)
55. Frei E 3rd, Holland JF, Schneiderman MA, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 1958;13:1126-1148.
56. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243-4251.
57. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007;7:216-223. (Pubitemid 47437268)
58. Ricevuto E, Bruera G, Marchetti P. General principles of chemotherapy. Eur Rev Med Pharmacol Sci 2010;14:269-271.
59. Chiu GN, Wong MY, Ling LU, et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr Drug Metab 2009;10:861-874.
60. Krishnamurthy P, Schuetz JD. The ABC transporter Abcg2/ Bcrp: role in hypoxia mediated survival. Biometals 2005;18:349-358. (Pubitemid 41298019)
61. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279:24218-24225. (Pubitemid 38725283)
62. Hamada H, Tsuruo T. Purification of the 170- to 180- kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 1988;263:1454-1458. (Pubitemid 18039953)
63. McKenzie JL, Takenaka K, Gan OI, Doedens M, Dick JE. Low rhodamine 123 retention identifies long-term human hematopoietic stem cells within the Lin-CD34CD38- population. Blood 2007;109:543-545. (Pubitemid 46105951)